http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2588835-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ad8d2e91732feb626589e8d0735b7496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate | 2014-11-27^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-07-10^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddb7cfaf39c3e0339c95466f3ca5c393 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e398d5b3d6b3ac3e5f3cdf6e0bea27a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2225ebf83ee2c5d949eb7909be8d9325 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9c9aca936cfc84d60ea95923300b159 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_040dcfa9690f2dc9b68287142a3885a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b78df128cc2e37dfbfc1ca7f9d1ecdbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c501161a7ced6aba234569a0e4f91c30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbcb1013ec78ae2e6c3703dad4a5be5d |
| publicationDate | 2016-07-10^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2588835-C1 |
| titleOfInvention | Method for therapy of skin damages and biotransplant therefor |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, specifically to biotechnology, and can be used for treating skin damages. Invention uses a tissue-engineered structure based on autologous fibroblast on biodegradable matrix and its application on wound. Fibroblasts transfected with, built ino plasmid vectors, genes hPOT1 (Adgene Plasmid 12387) and hPOT1 delta OB (Adgene Plasmid 13241) using a set of Lipofectamine™ 2000 (Invitrogen) according to manufacturer's protocol. Method then includes cultivation in DMEM with additionof 10 % FBS, 10 ng/ml FGF, 100 units/ml penicillin, 100 mcg/ml of streptomycin and 1 mcg/ml puramycin. During cultivation, transfected cells are selected according to resistance puramycin medium containing 1 mcg/ml puramycin. n EFFECT: use of said tissue-engineered structure provides ectopic expression of telomerase genes, increases length of telomeres and high proliferative cell potential of biograft, wherein vectors function in fibroblasts of biograft for first 3-4 weeks after application, providing resistane of cells to aggressive wound content. n 3 cl, 11 tbl, 2 dwg |
| priorityDate | 2014-11-27^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 149 of 149.